These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1868 related articles for article (PubMed ID: 28201977)

  • 21. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
    Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.
    Karp Leaf R; Cho HJ; Avigan D
    Curr Hematol Malig Rep; 2015 Dec; 10(4):395-404. PubMed ID: 26338470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma.
    Atanackovic D; Luetkens T; Radhakrishnan S; Kroger N
    Curr Cancer Drug Targets; 2017; 17(9):839-845. PubMed ID: 28875836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.
    Neri P; Bahlis NJ; Lonial S
    Clin Cancer Res; 2016 Dec; 22(24):5959-5965. PubMed ID: 27797968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.
    Podar K; Pecherstorfer M
    Expert Opin Pharmacother; 2017 Aug; 18(11):1061-1079. PubMed ID: 28604120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in immunotherapy in multiple myeloma.
    Boussi L; Niesvizky R
    Curr Opin Oncol; 2017 Nov; 29(6):460-466. PubMed ID: 28877078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.
    Lee SJ; Borrello I
    Cancer Treat Res; 2016; 169():207-225. PubMed ID: 27696265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.
    Zannetti BA; Faini AC; Massari E; Geuna M; Maffini E; Poletti G; Cerchione C; Martinelli G; Malavasi F; Lanza F
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunotherapy for the treatment of multiple myeloma.
    Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
    Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
    Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
    Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune therapy in multiple myeloma.
    Luptakova K; Avigan D
    Clin Adv Hematol Oncol; 2015 Nov; 13(11):767-75. PubMed ID: 27058703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
    Tai YT; Cho SF; Anderson KC
    Front Immunol; 2018; 9():1822. PubMed ID: 30147691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Immune Therapies for Myeloma.
    Rosenblatt J; Avigan D
    J Natl Compr Canc Netw; 2015 Nov; 13(11):1440-7. PubMed ID: 26553769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibody therapy in multiple myeloma.
    Touzeau C; Moreau P; Dumontet C
    Leukemia; 2017 May; 31(5):1039-1047. PubMed ID: 28210004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the bone marrow microenvironment in multiple myeloma.
    Kawano Y; Moschetta M; Manier S; Glavey S; Görgün GT; Roccaro AM; Anderson KC; Ghobrial IM
    Immunol Rev; 2015 Jan; 263(1):160-72. PubMed ID: 25510276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular immunotherapy as a therapeutic approach in multiple myeloma.
    Liegel J; Avigan D; Rosenblatt J
    Expert Rev Hematol; 2018 Jul; 11(7):525-536. PubMed ID: 29856648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 94.